PolyNovo

Aging Populations Are Set To Expand Global Advanced Tissue Care

AnalystHighTarget

Not Invested

Consensus Narrative from 9 Analysts

Published

30 Jul 25

Updated

28 Aug 25

AnalystHighTarget's Fair Value

AU$2.65

48.9% undervalued

28 Aug

AU$1.36

-42.8%

20.4%

-42.8%

20.4%

Author's Valuation

AU$2.7

48.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

AU$2.7

48.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

15.00%

Medical Equipment revenue growth rate

0.45%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.14%

Calculation

AU$53.16m

Earnings '28

42.30x

PE Ratio '28

AU$2.25b

Market Cap '28

AU$2.25b

Market Cap '28

690.84m

No. shares '28

AU$3.25

Share Price '28

AU$3.25 Share Price '28

Discounted to 2025 @ 7.14% p.a.

AU$2.65

Fair Value '25